1. Meaning 

A decentralized biobank governance model is a system in which multiple hospitals, universities, laboratories, research institutions, or community-based repositories collect and manage biological samples and associated health data under a shared framework of ethical, legal, and technical rules.

A biobank may contain blood, tissue, DNA, cells, reproductive material, or other biological specimens, together with clinical and genomic information.

Unlike a centralized model, where a single institution controls most samples and decisions, a decentralized model distributes responsibilities among participating institutions while coordinating access, consent, privacy, quality, and research oversight.

A recent scholarly proposal, Decentralized Biobanking for Transparency, Accountability, and Engagement in Biospecimen Donation (2025), examines technology-enabled governance that gives donors greater visibility into research uses and promotes continuing engagement.

SSRN

How decentralized governance works

Donors and research participants

Consent, privacy rights, permitted uses and participation choices

Hospital biobank

Collects and stores specimens

University repository

Research and laboratory analysis

Data custodian

Access controls and secure data linkage

Ethics and governance committee

Independent review and accountability

Shared governance framework

Common consent rules · Data-transfer agreements · Audit trails · Remedies for misuse

The essential legal distinction is that decentralization distributes operational control but does not eliminate legal accountability. Every participating institution must comply with the law applicable to its own activities, and agreements must identify who is responsible for each decision.

2. Principal decentralized governance models

Korean researchers begin collecting 1 million genetic samples for rare disease study - CHOSUNBIZ

A. Federated biobank model

Each institution retains physical custody of its samples and identifiable records. A shared platform allows approved researchers to discover available specimens or perform authorized analyses without routinely transferring the underlying material.

Legal focus: institutional responsibility, access permissions, privacy protection, and research agreements.

The national infrastructure to boost personalized health research is up and running | SIB Swiss Institute of Bioinformatics

B. Distributed data-network model

Clinical and genomic data remain in separate repositories, but approved queries or analyses can run across participating institutions.

Legal focus: data-controller responsibilities, cybersecurity, re-identification risks, and cross-border transfers.

Navigating Medical Ethics and Healthcare Law: A Guide for...

C. Consortium governance model

Universities, hospitals, public agencies, and private research partners establish a joint charter, common access rules, ethics-review arrangements, and dispute-resolution procedures.

Legal focus: allocation of liability, conflicts of interest, intellectual property, benefit-sharing, and withdrawal rights.

eConsent — RAMLA ALI

D. Donor-participatory model

Donors may be able to review research uses, update preferences, receive appropriate information, and exercise available consent or withdrawal rights through a digital system.

Legal focus: valid consent, transparency, limits on withdrawal, return of clinically relevant findings, and equitable participation.

Federated microservices architecture with blockchain for privacy-preserving and scalable healthcare analytics | Scientific Reports

E. Blockchain-assisted governance

A distributed ledger may record permissions, transfers, approvals, and audit events. Biological samples themselves are normally stored in physical facilities, while sensitive data should not be placed directly on an immutable public ledger.

Legal focus: data minimization, correction and deletion rights, security, governance of encryption keys, and the legal effect of recorded permissions.

These models can be combined. For example, a federation of hospital biobanks may use a consortium agreement, centralized ethics coordination, decentralized sample storage, and a donor-facing consent portal.

3. Legal framework in India

India is particularly important when assessing decentralized biobanks because the governance framework combines constitutional protections, biomedical research ethics, data protection legislation, institutional policies, and contractual arrangements.

A. ICMR National Ethical Guidelines, 2017

The Indian Council of Medical Research's National Ethical Guidelines for Biomedical and Health Research Involving Human Participants contains a dedicated Section 11 on biological materials, biobanking, and datasets.

The guidelines address:

Informed consent, including broad and tiered consent where ethically appropriate.

Storage and management of identified, coded, and anonymized specimens.

Ethics committee review and oversight of secondary research.

Technical authorization committees for sample collection, distribution, and data access.

Material Transfer Agreements (MTAs) and Data Transfer Agreements (DTAs).

Standard operating procedures for collection, storage, retrieval, sharing, and disposal.

Contingency planning for repositories.

Indian Council of Medical Research+1

Section 11.6 is especially relevant to decentralized systems: it contemplates technical authorization committees with scientific, ethical, and external representation, and coordination with the institutional ethics committee.

These guidelines provide an important governance framework, but they should not automatically be treated as equivalent to a comprehensive, standalone biobanking statute.

B. Constitutional right to privacy

In Justice K.S. Puttaswamy (Retd.) v. Union of India (2017), the Supreme Court of India recognized privacy as a fundamental right protected by Article 21 and other freedoms under Part III of the Constitution. The judgment emphasized informational privacy, individual autonomy, dignity, and safeguards against unjustified intrusion.

NHRC+1

Application to decentralized biobanks: a network that links genetic samples with identifiable medical records must consider whether collection, access, retention, sharing, or disclosure interferes with privacy and whether the relevant processing has a lawful basis and adequate safeguards.

The judgment is not specifically a biobank decision. Its constitutional principles are relevant by analogy, particularly where public authorities or state-linked institutions are involved.

C. Data protection legislation

India's Digital Personal Data Protection Act, 2023, and its applicable rules and commencement provisions must be considered for personal data processed by biobanks. The legal analysis should distinguish identifiable personal data from biological specimens themselves and assess the particular processing activity, applicable exemptions, and the law in force at the relevant time.

A DNA sample is not automatically treated identically to every item of digital personal data; its legal treatment depends on the applicable law and circumstances. Removing names alone may also fail to prevent identification through genetic information or linkage with other datasets.

D. International legal frameworks

The GDPR's Article 89 requires safeguards for scientific research processing, including appropriate technical and organizational measures and data minimization. Where applicable, those obligations must be implemented across the participating organizations rather than assumed to be satisfied by a shared platform alone.

Better Regulation+2

4. Important case laws and their application

There is no single landmark judgment that comprehensively establishes a universal legal framework for decentralized biobanks. The relevant case law instead addresses ownership of donated specimens, informed consent, research commercialization, genetic information, and privacy. These principles help determine how a decentralized network should be governed.

Case 1. Moore v. Regents of the University of California (1990)

Citation: 793 P.2d 479 (Cal. 1990) · Supreme Court of California

Facts: John Moore's tissue was used in research that led to the development of a commercially valuable cell line. He alleged that his physicians had failed to disclose their research and commercial interests.

Judgment: The court rejected his conversion claim based on ownership of the excised cells, but recognized that claims relating to a physician's breach of fiduciary duty and failure to obtain informed consent could proceed.

Justia Law

Legal principles

A patient's lack of a proprietary claim over excised tissue does not eliminate the physician's disclosure obligations.

Research and commercial interests can create conflicts that require appropriate disclosure.

Ownership of specimens and ethical authority to use them are separate questions.

Application to decentralized biobanks: A hospital cannot assume that physical possession of a sample authorizes every future use. The network should record the scope of the donor's consent, any applicable restrictions, and relevant commercial interests.

Case 2. Greenberg v. Miami Children's Hospital Research Institute (2003)

Citation: 264 F. Supp. 2d 1064 (S.D. Fla. 2003) · US District Court

Facts: Families affected by Canavan disease and supporting organizations contributed biological materials and research assistance to identify the disease-associated gene. Disputes arose after the gene was patented and exclusive licensing arrangements restricted access to resulting tests.

Judgment: The court dismissed several claims, including conversion and lack of informed consent as pleaded, while allowing an unjust-enrichment claim to survive the motion to dismiss. The ruling was not a final determination that the plaintiffs were entitled to a particular share of commercial profits.

PubMed+1

Legal principles

Donating tissue does not automatically confer ownership of every later discovery.

The terms and circumstances of participation can matter to disputes about commercialization.

Collaboration agreements should clarify intellectual-property rights, licensing expectations, and benefit-sharing arrangements.

Application: A decentralized biobank consortium should establish commercial-use policies before specimens are distributed, particularly where public hospitals, patient organizations, universities, and pharmaceutical companies collaborate.

Case 3. Washington University v. Catalona (2007)

Citation: 490 F.3d 667 (8th Cir. 2007) · US Court of Appeals for the Eighth Circuit

Facts: A university and a former researcher disputed control over biological samples donated for prostate-cancer research. The researcher sought to transfer the samples to another institution.

Judgment: The court upheld the university's ownership of the specimens under the circumstances and governing Missouri law. Donors who had contributed samples for research conducted under the university's auspices did not retain the asserted proprietary right to direct their transfer to the former researcher.

Justia Dockets & Filings+1

Legal principles

Custody and ownership disputes can arise when researchers move between institutions.

Donor authorization, institutional agreements, and the circumstances of donation are significant.

A change in personnel does not automatically transfer control of an institutional collection.

Application: Every decentralized network needs a specimen-custody register, transfer authorization rules, and a procedure for staff departures, institutional withdrawal, and repository succession.

Case 4. Justice K.S. Puttaswamy (Retd.) v. Union of India (2017)

Citation: (2017) 10 SCC 1 · Supreme Court of India, nine-judge bench

Facts: The Court considered whether privacy is constitutionally protected under Indian law in proceedings concerning the Aadhaar scheme.

Judgment: The Court unanimously recognized privacy as a fundamental right, including informational privacy, under Article 21 and the freedoms guaranteed by Part III of the Constitution.

NHRC+1

Legal principles

Privacy protects dignity, autonomy, and control over personal information.

Intrusions by the state require a valid legal basis and must satisfy constitutional standards.

Informational privacy requires attention to how personal information is collected, used, and disclosed.

Application: Publicly funded or state-operated biobanks should establish lawful access criteria, restrictions on secondary uses, security controls, and review mechanisms for sensitive genomic data.

Important limitation: Puttaswamy is a general constitutional privacy decision, not a ruling specifically about biobanks or genomic databases. Its application depends on the facts, the institution involved, and the relevant law.

Case 5. Association for Molecular Pathology v. Myriad Genetics, Inc. (2013)

Citation: 569 U.S. 576 (2013) · Supreme Court of the United States

Facts: The dispute concerned patents covering the BRCA1 and BRCA2 genes associated with hereditary cancer risk.

Judgment: The Court held that naturally occurring DNA segments are not patent-eligible merely because they have been isolated, while synthetically created complementary DNA (cDNA) may be patent-eligible under the circumstances addressed by the judgment.

Justia U.S. Supreme Court Center+1

Legal principles

Discovery of naturally occurring genetic information is distinct from creating a patent-eligible invention.

Genetic information, biological specimens, and inventions derived from them are legally distinct.

Patent eligibility does not resolve donor-consent, privacy, ownership, or benefit-sharing questions.

Application: A decentralized consortium should separate specimen-access permissions from intellectual-property licensing. Permission to analyze a sample should not be confused with unrestricted rights to commercialize resulting inventions.

Comparative summary

These decisions come from different jurisdictions and do not establish a uniform rule for all biobanks. In particular, US specimen-ownership decisions should not be applied automatically to India or other legal systems.

5. Core legal duties in a decentralized biobank

A. Informed consent and secondary research

A decentralized system may permit samples collected at one hospital to be used by researchers at another institution, sometimes years later. Consent procedures should therefore explain, as far as reasonably possible:

The purposes for which specimens and associated data may be used.

Whether future research, genomic sequencing, international sharing, or commercial research is anticipated.

Whether samples will be identifiable, coded, or irreversibly anonymized.

How donors can exercise applicable withdrawal or preference-changing rights.

Whether individual research findings may be returned and under what conditions.

Broad consent can support future research in appropriate circumstances, but it does not provide unlimited permission for every conceivable use. New uses outside the consent or legally authorized framework may require additional consent, ethics review, or another valid authorization.

B. Privacy and cybersecurity

Distributed systems can reduce the need to move identifiable information, but they also create additional access points and potential security weaknesses.

Recommended safeguards include:

Pseudonymization and separate storage of identity keys.

Role-based access controls and multifactor authentication.

Encryption during storage and transmission.

Audit logs recording access, approvals, transfers, and attempted unauthorized use.

Risk assessments before connecting new repositories or datasets.

Incident-response procedures and applicable breach notifications.

Genomic data require particular caution because a person's identity may sometimes be inferred by combining genetic information with other datasets. Merely removing names does not necessarily make genetic data anonymous.

C. Accountability and liability

A network agreement should allocate responsibilities among the institutions rather than rely on a general statement that all participants will comply with the law.

Liability depends on the applicable law, the conduct of each party, and the facts of the particular case. A consortium agreement cannot simply contract away statutory obligations or the rights of donors.

6. Institutional governance architecture

A legally robust decentralized network should establish several complementary levels of oversight.

Level 1 — Network governing council

Establishes shared policies, approves the governance charter, allocates responsibilities, and supervises conflicts of interest and institutional compliance.

Level 2 — Ethics and scientific review

Evaluates scientific validity, participant protections, secondary use, community concerns, and whether proposed research fits the approved consent framework.

Level 3 — Local repository managers

Maintain specimen integrity, provenance, storage quality, consent records, access logs, and local compliance procedures.

Level 4 — Independent audit and donor representation

Reviews compliance, investigates complaints, evaluates whether consent restrictions are respected, and provides channels for donor or community participation.

The governing charter should be supported by material-transfer agreements, data-access agreements, confidentiality terms, intellectual-property policies, and procedures for resolving disputes.

7. Special issues: blockchain, commercialization, and institutional failure

Blockchain governance. A distributed ledger can provide tamper-evident records of approvals and transfers, but it cannot establish that consent was valid, that a research purpose is ethical, or that an institution has legal authority to release a sample. Sensitive personal information should generally be kept off immutable public ledgers.

Commercialization and benefit-sharing. Agreements should address patentable inventions, licensing revenue, research costs, public-interest access, and any promised benefits to participating communities. The legal position should be specified before samples are distributed, not negotiated only after a valuable discovery.

Institutional insolvency. A biobank should not treat samples as ordinary commercial assets without considering donor commitments, applicable privacy rules, and the legal status of the collection. Italian scholarship discussing biobank insolvency highlights the risks of leaving sample custody and data-processing responsibilities unresolved when public and private partners separate.

Springer Nature Link+1

Withdrawal and deletion. A donor's request to withdraw should trigger a documented assessment of what can lawfully and practically be stopped, returned, or deleted. Withdrawal may not undo completed analyses or eliminate data already incorporated into aggregate results. Any limits should be explained in advance and grounded in the applicable framework.

8. Practical compliance blueprint for India

For an Indian hospital–university–industry biobank network, the following sequence provides a practical starting point.

Map the participating institutions. Identify each specimen custodian, data holder, research sponsor, service provider, and intended recipient.

Establish the legal basis. Review the ICMR guidelines, applicable ethics requirements, data-protection legislation and commencement rules, sector-specific requirements, and relevant contractual obligations.

Create a common consent framework. Document approved research categories, commercial uses, international transfers, donor preferences, and withdrawal procedures.

Adopt a governance charter. Define committee authority, access decisions, escalation procedures, conflicts of interest, and the responsibility of each institution.

Execute transfer and access agreements. Specify permitted purposes, security requirements, onward-transfer restrictions, intellectual property, publication, return or destruction of samples, and remedies for breach.

Implement technical safeguards. Maintain specimen identifiers, provenance records, controlled access, audit trails, backup systems, and documented incident response.

Plan for failure and succession. Decide what happens if a repository closes, a partner leaves, a cyber incident occurs, or a proposed research use is no longer authorized.

Review and audit periodically. Reassess consent, access permissions, security, scientific quality, and institutional compliance as the network grows.

The ICMR's Section 11 is a particularly useful starting point for Indian implementation, including its requirements concerning technical authorization committees, ethics oversight, and material- and data-transfer agreements.

Indian Council of Medical Research+1

9. Critical evaluation

A centralized system may be easier to administer, but it can concentrate control and create a single point of failure. A decentralized system may improve collaboration and institutional resilience, but only if shared rules are enforceable, responsibilities are clear, and every participating repository maintains adequate safeguards.

10. Conclusion

Decentralized biobank governance is best understood as a federated system of specimen custody, data stewardship, scientific collaboration, and shared accountability.

The central lessons from Moore, Greenberg, Catalona, Puttaswamy, and Myriad Genetics are that specimen possession does not settle every consent question, commercialization can create disputes about donor expectations, institutional control must be clearly defined, privacy remains a fundamental concern, and access to biological material is distinct from ownership of resulting intellectual property.

For India, the most defensible approach is to combine the ICMR ethical framework with applicable statutory requirements, independent ethics review, robust transfer agreements, secure data infrastructure, and explicit plans for withdrawal, commercialization, and institutional failure.

The ultimate objective is not merely to distribute samples across institutions. It is to ensure that research remains scientifically useful, ethically justified, legally compliant, and accountable to the people whose biological materials make it possible.

This is a comparative legal overview for research and educational purposes, not jurisdiction-specific legal advice. The cited cases have different precedential force in different countries, and the legal requirements for a particular biobank must be verified against the law applicable to its activities.